First-Line Oral Antibiotics for Non-Purulent Cellulitis
For non-purulent cellulitis, use a beta-lactam antibiotic targeting beta-hemolytic streptococci: specifically cephalexin 500 mg four times daily, penicillin, or amoxicillin for 5-6 days. 1, 2
Primary Antibiotic Choices
The cornerstone of treatment for non-purulent cellulitis (cellulitis without purulent drainage, exudate, or abscess) is coverage against beta-hemolytic streptococci, as these are the primary pathogens 1, 3, 1. The IDSA guidelines explicitly state that empirical therapy for beta-hemolytic streptococci is recommended, while the role of community-acquired MRSA is unknown in this presentation 1, 3.
Recommended First-Line Options:
- Cephalexin: 500 mg four times daily (adults); 25-50 mg/kg/day in 3-4 divided doses (children) 4
- Penicillin: Standard dosing for streptococcal coverage 2
- Amoxicillin: Standard dosing 1
- Dicloxacillin: 250-500 mg four times daily (adults); 25-50 mg/kg/day in 4 divided doses (children) 4
Recent evidence from the American College of Physicians (2021) supports a 5-6 day course rather than the traditional 10-14 days, particularly for patients who can self-monitor with close follow-up 2. This represents an important update from the 2011 IDSA guidelines which recommended 5-10 days 1, 3.
When to Add MRSA Coverage
Do NOT routinely cover MRSA in non-purulent cellulitis 1, 5, 6. However, add MRSA-active therapy if:
- Patient fails to respond to beta-lactam therapy after 48-72 hours 1, 3
- Systemic toxicity is present 1
- Penetrating trauma is involved 2
- Evidence of MRSA infection elsewhere or nasal colonization 2
- Injection drug use 2
- SIRS criteria are met 2
If MRSA Coverage Needed:
Combination therapy options (to maintain streptococcal coverage):
- TMP-SMX (1-2 double-strength tablets twice daily) PLUS a beta-lactam (e.g., amoxicillin or cephalexin) 1, 3
- Doxycycline (100 mg twice daily) PLUS a beta-lactam 1, 3
- Clindamycin alone (300-450 mg four times daily) - provides both streptococcal and MRSA coverage 1, 3
Critical Clinical Pitfalls
Don't Confuse Purulent vs Non-Purulent
This distinction is crucial for antibiotic selection. Non-purulent cellulitis has:
- No purulent drainage or exudate
- No drainable abscess
- Diffuse erythema, warmth, swelling, tenderness
If purulent features are present, MRSA coverage becomes first-line 1, 3.
Avoid TMP-SMX or Tetracyclines as Monotherapy
These agents have poor activity against beta-hemolytic streptococci and should never be used alone for non-purulent cellulitis 1, 6. A systematic review confirmed that beta-lactams remain the treatment of choice for non-purulent cellulitis 6.
Geographic Considerations
In areas with high community-acquired MRSA prevalence, there may be temptation to empirically cover MRSA. However, even in MRSA-prevalent settings, the evidence shows non-purulent cellulitis is predominantly streptococcal 5. Start with beta-lactams and escalate only if no clinical response 1, 7.
Duration of Therapy
Treat for 5-6 days in uncomplicated cases with close follow-up 2. The 2021 ACP guidelines represent the most recent high-quality recommendation, updating from the traditional 5-10 day courses. Extend treatment only if:
- No improvement after 5 days 2
- Extensive disease
- Immunocompromised host
- Slow clinical response
Pediatric Modifications
- Cephalexin: 25-50 mg/kg/day in 3-4 divided doses 4
- Avoid tetracyclines in children <8 years of age 3, 1, 3
- Clindamycin is an important option for children when MRSA coverage is needed: 20-30 mg/kg/day in 3 divided doses 3, 1
Penicillin Allergy
For patients with non-immediate hypersensitivity reactions:
- Cephalexin or other first-generation cephalosporins are safe 4
For immediate hypersensitivity (anaphylaxis):
- Clindamycin 300-450 mg four times daily 4
- Avoid beta-lactams entirely